Drug intelligence / Profile preview

Z-100

Development stage: Phase 3
Lead developer: Zeria Pharmaceutical
Modality: Small Molecules
Administration: Subcutaneous

Overview

Z-100 is an immunomodulating agent originally extracted from human tubercle bacilli. It is designed to modify the immune system's behavior and has been developed primarily by Zeria Pharmaceutical. The drug acts as an immunomodulator and has demonstrated anti-inflammatory, antineoplastic (anticancer), and antiviral properties. In Japan, it has been launched for the treatment of leucopenia (a reduction in white blood cells). It has also reached phase III clinical trials for cervical cancer in several Asian countries but was discontinued for HIV infections and rheumatoid arthritis[4][3][8].

Brand names: Z-100Z100Z 100
Other names: SSMAncer20Ancer-20Ancer 20

Targets

NOD2 (Nucleotide-binding oligomerization domain-containing protein 2)

Beyond the preview

Go deeper on Z-100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Z-100.

Explore the full profile